IL17A and psoriasis: Traditional therapeutic approaches, such as methotrexate and cyclosporine, have been utilized to manage psoriasis by inhibiting systemic immunity since the 1980s.[3] However, their applications are hindered due to the associated risks, including infections and malignancies.[1, 4] Recently developed bioagents targeting key cytokines involved in psoriasis pathogenesis, such as IL‐17A, and IL‐23, have shown efficacy in alleviating psoriatic symptoms.[5] Despite their benefits, completely curing the disease by merely neutralizing cytokines from the overactive immune system remains challenging.[6]